NCT06872359进行中（未招募）不适用
Prospective, Multicentric, Open Label Clinical Investigation to Evaluate Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 210
- 试验地点
- 5
- 主要终点
- Assessment of improvement of KIO017 device range on GAIS (Global Aesthetic Improvement Scale)
研究概览
简要总结
The goal of this clinical trial is to primarily evaluate the performance of KIO017 in filling/volumizing after injection in different areas in healthy women or men, older than 18 years and seeking an improvement of her/his face aspect with resorbable filler. The main questions it aims to answer are:
If the products are safe
- Acceptable local tolerance, with acceptable clinical signs after injection.
If the clinical performance is as intended compared to baseline
- Evaluation of performance by assessing the improvement of the appearance of the defect to be corrected by using Global Aesthetic Improvement Scale (GAIS)
- Quantification of the improvement using the appropriate scale when available or other appropriates tool (angle for chin, for instance).
- Pain felt during injection and after injection
- Subject satisfaction
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Subject
- •Sex: male or female
- •Age: more than 18 years
- •Subject seeking an improvement of her/his face aspect with resorbable filler
- •The subjects must meet a criterion according to the treatment indication specific scale (Asher Face Volume Loss Scale (FVLS), Bazin Ptosis of the Lower part of the Face Scale (PLFS), temple hollow scale (THS), Wrinkle Severity Rating Scale (WSRS), Bazin Marionette Lines scale (MLS), Bazin Upper Lip Wrinkle Scale (ULWS), Rossi scale)
- •Subject having given their free, express, and informed consent
- •Subject psychologically able to understand the information related to the study, and to give their written informed consent
- •Subject affiliated to a health social security system
- •Women of childbearing potential should use a contraceptive method considered effective since at least 12 weeks and throughout the study
- •Women of childbearing potential must have a negative urinary pregnancy test on D0
排除标准
- •Pregnant or nursing woman or planning a pregnancy during the study.
- •Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship
- •Subject in a social or sanitary establishment
- •Subject participating to another clinical research or being in an exclusion period for a previous study
- •In France: subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study
- •Subject already included in another group of this study
- •Subject having received treatment with a laser, ultrasound or radiofrequency treatment, a dermabrasion, a surgery, a chemical peeling or any other procedure based on active dermal response on the face in the 6 previous months
- •Subject having received mesotherapy products or botulinum toxin in the same area in the 6 previous months
- •Subject having received resorbable filling product (e.g., hyaluronic acid) injections in the same area in the 12 previous months
- •Subject having received slowly resorbable filling product (e.g., calcium hydroxyapatite, polycaprolactone, polylactic acid) injections in the same area or resorbable threads in the 24 previous months
- •Subject having received injections of permanent products in the face (e.g., acrylate polymers, silicone, polytetrafluoroethylene)
- •Subject having received facial or cervico-facial lifting in the 24 previous months
- •Subject wearing skin support device (mesh, gold threads, permanent lifting threads) on the face
- •Subject with uncontrolled and/or recently recovered (<6 months) depression or psychiatric disorders or any other disorder that may pose a health risk to the subject in the study and/or may have an impact on the study assessments
- •Subject with severe, ongoing and uncontrolled diseases such as malignancy or history of malignancy, type I diabetes, liver failure, renal failure, lung/heart disease, neoplasia, malignant blood disease, HIV, or other major disease (e.g., systemic fungal infection)
- •Subject with recurrent porphyria, untreated epilepsy, coronary insufficiency, ventricular rhythm disorders, severe hypertension, obstructive cardiomyopathy, hyperthyroidism
- •Subject with any skin or systemic disease (acute and/or chronic), in the previous year, likely to interfere with the measured parameters or to put the subject to an undue risk
- •Subject with known history of or suffering from autoimmune disease and/or immune deficiency
- •Subject with current cutaneous inflammatory or infectious processes (e.g., acne, herpes, mycosis, papilloma, chronic eczema, atopic dermatitis …), abscess, unhealed wound, or a cancerous or precancerous lesion on the face
- •Subject with multiple allergies, anaphylactic shock history, evolutive allergic pathologies, history of granulomatous diseases
- •Subject with known hypersensitivity to chlorhexidine
- •Subject having history of allergy or hypersensitivity to one of the components of the tested device, like hyaluronic acid, lidocaine or other amine-type local anaesthetics. polysaccharides of edible mushrooms
- •Subject predisposed to keloids or hypertrophic scarring
- •Subject with coagulation and/or homeostasis disorders
- •Subject with evidence of lymphatic or venous stasis or serious blood disorders
- •Subject with pigmentation disorders
- •Subject with history of Streptococcus disease (recurrent sore throats, acute rheumatic fever)
- •Subjects with congenital methemoglobinemia or receiving concomitant treatment with methaemoglobin-inducing agents
- •For subject injected in the chin: subject with clinically significant malocclusion (severe overbite), having dentures and/or any device covering the palate that would interfere with visual assessment of the chin area
- •Subject with tattoos, piercings, facial hairs mole or scar that would interfere with visual assessment on the injected area
- •Subject with symptoms consistent with COVID-19 or suffering from ongoing symptoms from previous COVID-19 infection
- •Subject under anti-coagulant treatment (such as aspirin, nonsteroidal anti-inflammatory drugs) or treatment liable to interfere with the healing process or hemostasis, within 1 month prior to injection, and one-month post-injection.
- •Subject with a treatment that reduces or inhibits hepatic metabolism (cimetidine, beta-blockers, etc..)
- •Subject having received a vaccine within 21 days prior to injection or planning to do in the 14 days post-injection
- •Subject having received dental care within 6 weeks prior to the study or planning to have dental care within 6 weeks post-injection
- •Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk
- •Subject undergoing a topical (on the face) or systemic treatment:
- •anti-inflammatory medication and/or antihistamines within 2 weeks prior to injection, and 1 month post-injection
- •corticosteroids within 1 month prior to injection, and 1-month post-injection
- •retinoids and/or immunosuppressors within 3 months prior to injection and during the study
- •Intensive exposure to sunlight or UV-rays within the previous month and/or planning to do so during the study
- •Heavy smoker (subject who reports smoking 10 or more cigarettes per day);
- •Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day)
研究组 & 干预措施
Group 1 (KIO017-1)
Experimental
Subject seeking an improvement in at least one of the following indications: chin retrusion, mid-face deficit, jawline ptosis
干预措施: KIO017-1 (Device)
Group 2 (KIO017-2)
Experimental
Subject seeking an improvement in at least one of the following indications: temple volume deficit, moderate to severe nasolabial folds, moderate to severe marionette lines, mid-face deficit
干预措施: KIO017-2 (Device)
Group 3 (KIO017-3)
Experimental
Subject seeking an improvement in lip volume/contour and/or perioral lines.
干预措施: KIO017-3 (Device)
结局指标
主要结局
Assessment of improvement of KIO017 device range on GAIS (Global Aesthetic Improvement Scale)
时间窗: The measurement is performed on Month 3 after the injection
Proportion of indications having an improvement with the overall KIO017 range of devices as assessed by the investigator in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))
Assessment of Safety
时间窗: Evaluation is performed on the Month 1 after injection.
Assessment of number and percentage of subjects with Adverse Device Effects (ADEs). ADEs are defined as any adverse event related to the use of the investigational medical device.
次要结局
- Assessment of proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the subject in live(Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the investigator in live(Measurement of improvement after injection on the Month 1, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of each product and proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the investigator in live(Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of each indication and proportion of subjects having an improvement on GAIS (Global Aesthetic Improvement Scale) by the investigator in live(Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of improvement on Bazin Ptosis of the Lower part of the Face Scale (PLFS)(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24)
- Assessment of improvement on Wrinkle Skin Rating Scale (WSRS)(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24)
- Assessment of each indication, proportion of subjects having an improvement on GAIS (Global Aesthetic Improvement Scale) by the subject in live(Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of improvement on Ascher Face Volume Loss Scale (FVLS)(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24)
- Assessment of improvement on Temple Hollow Scale (THS)(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24)
- Assessment of each product, proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the subject in live(Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of the improvement via glabella-subnasal-pogonion facial angle(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24)
- Assessment of improvement on Bazin Marionette Lines Scale (MLS)(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 12, Month 18 and Month 24)
- Assessment of improvement on Rossi scale(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12 (for upper lip and lower lip))
- Assessment of performance on Bazin Upper Lip Wrinkle Scale (ULWS)(Measurement of change/proportion of subjects with improvement after injection on the Month 1, Month 3, Month 6, Month 9 and Month 12)
- Assessment of average pain on Visual Analog Scale (VAS)(One hour after the last injection and each day for two days after each injection session)
- Assesmment of injector satisfaction via questionnaire(Questionnaire completed immediately after each injection session: Day 0, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of subject satisfaction via questionnaire(On Day 0 before the injection and at each timepoint: Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of local tolerance on Injection Site Reactions (ISRs) scale reported by the subjects(During one month after each injection session on the daily-log: Day 0, Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Assessment of local tolerance on Injection Site Reactions (ISRs) scale evaluated by the investigator(On Day 0 after the injection and after each injection session: on Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24)
- Number of AEs (Adverse Effects) and ADEs (Adverse Device Effects)(From the first injection and till the Month 24)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
不适用
Evaluation of Performance and Safety of KIO015 in Face Tissue FillingSkin QualityNCT05747690Kiomed Pharma78
尚未招募
2 期
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsHemophilia a and BNCT06747416Suzhou Alphamab Co., Ltd.24
已完成
2 期
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial DefectsPersistent Corneal Epithelial DefectNCT05436288Kiora Pharmaceuticals, Inc.10
进行中（未招募）
3 期
Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarVocal Fold ScarNCT05627648Kringle Pharma, Inc.62
终止
早期 1 期
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid TumorsSolid TumorsNCT04237649Novartis Pharmaceuticals77